CORE--Shared Resources Proteomics

核心--蛋白质组学共享资源

• 批准号: 7618849
• 负责人: Tomas M Mustelin
• 金额: $ 37.79万
• 依托单位: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7618849
• 关键词: Amino Acid Sequence; Antineoplastic Agents; Binding; Biochemical; Biological; Cancer Biology; Cancer Center; Carbohydrates; Chromatography; Complex; Development; Equipment; Event; Housing; Kinetics; Label; MALDI-TOF Mass Spectrometry; Mass Spectrum Analysis; Methods; Mission; NCI Center for Cancer Research; Peptide Sequence Determination; Peptides; Post-Translational Protein Processing; Procedures; Protein Analysis; Proteins; Proteome; Proteomics; Proteomics Shared Resource; Protocols documentation; Relative (related person); Research Personnel; Sampling; Services; Surface Plasmon Resonance; Techniques; Technology; Time; Training; base; cancer cell; drug discovery; instrument; interest; mass spectrometer; member; polypeptide; small molecule; technology development

DESCRIPTION (provided by applicant): The Cancer Center?s Proteomics Facility supports the Cancer Center?s investigators by providing access to and expertise in mass spectrometry (MS) and surface plasmon resonance (SPR). MS is a valuable technology to researchers interested in protein identification, characterization of post-translational modifications, peptides and carbohydrates, as well as global studies of the proteome of cancer cells. SPR provides real-time analysis of molecular interactions. The Proteomics Facility houses several mass spectrometers (MALDI-TOF, ESI-QQQ, and Q-TOF), HPLCs, a BIAcore 3000 instrument, and related analytical equipment. The facility is dedicated to the development and implementation of technology that will allow the Cancer Center investigators to analyze particular proteins on interest in detail or to perform broader proteome-based screens of polypeptide subsets relevant to cancer biology. The Specific Aims for the Facility are: 1. To contribute to the Cancer Center?s research by providing high-quality service and expertise in mass spectrometry and surface plasmon resonance, and to continue to train interested Cancer Center investigators in the use of our instruments and protocols. 2. To stay at the cutting edge of technology advances and opportunities in proteomics, and to keep members of the Cancer Center current in these technologies. 3. To engage in active development of new proteomics techniques, as well as serve as a platform for technology development by Cancer Center investigators. To assist the Cancer Center?s new Cancer Drug Discovery Initiative by developing mass spectrometry protocols for small molecules.

描述（由申请人提供）：癌症中心的蛋白质组学设施支持 癌症中心的研究人员通过提供质谱（MS）和表面等离子体共振（SPR）方面的访问和专业知识。 MS是一项有价值的技术，对于对蛋白质鉴定，翻译后修饰的表征，肽和碳水化合物的表征以及对癌细胞蛋白质组的全球研究的研究人员。 SPR提供了分子相互作用的实时分析。蛋白质组学设施包含多个质谱器（MALDI-TOF，ESI-QQQ和Q-TOF），HPLCS，BIACORE 3000仪器以及相关的分析设备。该设施致力于开发和实施技术，该技术将使癌症中心研究人员能够详细分析特定的蛋白质或进行与癌症生物学相关的多肽亚群的更广泛的基于蛋白质组的筛选。 该设施的具体目的是：1。通过在质谱和表面等离子体共振方面提供高质量的服务和专业知识来为癌症中心做出贡献，并继续培训感兴趣的癌症中心研究人员在使用我们的仪器和方案方面。 2。保持蛋白质组学技术进步和机遇的最前沿，并使癌症中心的成员在这些技术中保持最新状态。 3。积极开发新的蛋白质组学技术，并作为癌症中心研究人员的技术开发平台。通过为小分子制定质谱法方案来帮助癌症中心的新癌症药物发现计划。